We are live on ! Find out more
OMED

OncoMed Pharmaceuticals, Inc.
OMED

Delisted

OMED was delisted on the 22nd of April, 2019.

Back to rankings

55 hedge funds and large institutions have $154M invested in OncoMed Pharmaceuticals, Inc. in 2013 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 25 increasing their positions, 8 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 8

132% more capital invested

Capital invested by funds: $66.3M → $154M (+$87.4M)

13% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 15

4% more funds holding

Funds holding: 53 → 55 (+2)

Holders
55
Holders Change
+2
Holders Change %
+3.77%
% of All Funds
1.6%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
17
Increased
25
Reduced
8
Closed
15
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$12.8M
2
CCI
Columbus Circle Investors
+$6.33M
3
BFA
BlackRock Fund Advisors
California
+$5.83M
4
SAM
Sectoral Asset Management
Quebec, Canada
+$2.94M
5
Primecap Management
Primecap Management
California
+$1.76M

Top Sellers

Rank Fund Capital Flow
1
CII
CR Intrinsic Investors
Connecticut
-$4.14M
2
SCM
Sigma Capital Management
Connecticut
-$1.53M
3
JP Morgan Chase
JP Morgan Chase
New York
-$1.53M
4
WSA
Wall Street Associates
California
-$1.49M
5
BIT
BlackRock Institutional Trust
California
-$1.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
BIM
26
BlackRock Investment Management
Delaware
$378K +$13.2K +721 +6%
TCIM
27
TIAA CREF Investment Management
New York
$374K +$47.6K +2,600 +26%
ProShare Advisors
28
ProShare Advisors
Maryland
$371K +$230K +12,578 New
Charles Schwab
29
Charles Schwab
California
$362K +$6.59K +360 +3%
Morgan Stanley
30
Morgan Stanley
New York
$347K +$27.5K +1,503 +15%
Two Sigma Investments
31
Two Sigma Investments
New York
$300K +$186K +10,172 New
BA
32
BlackRock Advisors
Delaware
$294K +$39.5K +2,154 +28%
TAM
33
Tocqueville Asset Management
New York
$277K +$172K +9,400 New
Citadel Advisors
34
Citadel Advisors
Florida
$264K +$164K +8,953 New
California State Teachers Retirement System (CalSTRS)
35
California State Teachers Retirement System (CalSTRS)
California
$251K +$31.1K +1,700 +25%
Bank of Montreal
36
Bank of Montreal
Ontario, Canada
$207K +$128K +7,000 New
TA
37
Teachers Advisors
New York
$189K +$35.9K +1,957 +44%
BJ
38
BlackRock Japan
Japan
$159K -$696 -38 -0.7%
AIG
39
American International Group
New York
$147K +$70K +3,821 +327%
California Public Employees Retirement System
40
California Public Employees Retirement System
California
$146K – – –
Bank of America
41
Bank of America
North Carolina
$133K +$82.3K +4,490 New
Citigroup
42
Citigroup
New York
$125K +$77.7K +4,242 New
TRCT
43
Tower Research Capital (TRC)
New York
$121K +$71.5K +3,902 +1,951%
MCM
44
Mazama Capital Management
Oregon
$114K +$33.4K +1,824 +89%
NFA
45
Nationwide Fund Advisors
Ohio
$107K -$81.2K -4,432 -55%
Federated Hermes
46
Federated Hermes
Pennsylvania
$88K +$54.5K +2,977 New
SO
47
STRS Ohio
Ohio
$56K -$3.66K -200 -10%
U
48
UBS
Switzerland
$52K +$11.7K +641 +58%
CLOS
49
Compagnie Lombard Odier SCmA
Switzerland
$44K +$27.5K +1,500 New
QT
50
Quantbot Technologies
New York
$41K +$25.6K +1,400 New
1
2
3

OMED Hedge Fund Activity: Q4 2013 in Review

55 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q4 2013, worth a combined $154M — up 132% from $66.3M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new OMED positions and 15 closed out — a net gain of 2 holders — while 25 added to existing stakes and 8 trimmed.

The largest buyer was BVF Inc, adding an estimated $12.8M. The largest seller was CR Intrinsic Investors, exiting entirely with an estimated $4.14M sold.

  • 55 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q4 2013, up from 53 in Q3 2013.
  • Funds reported $154M of OncoMed Pharmaceuticals, Inc. stock for Q4 2013, up 132% quarter-over-quarter.
  • 17 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q4 2013 and 15 closed out, a net change of +2 holders.
  • The largest OncoMed Pharmaceuticals, Inc. buyer in Q4 2013 was BVF Inc, an estimated $12.8M added.
  • The largest OncoMed Pharmaceuticals, Inc. seller in Q4 2013 was CR Intrinsic Investors, an estimated $4.14M sold.

Based on aggregated 13F filings for Q4 2013.